Direct cyclodextrin based powder extrusion 3D printing of budesonide loaded mini-tablets for the treatment of eosinophilic colitis in paediatric patients

The purpose of this study was to combine direct powder extrusion (DPE) 3D printing and fluid bed coating techniques to create a budesonide (BD) loaded solid oral formulations for the treatment of eosinophilic colitis (EC) in paediatric patients. The preferred medication for EC treatment is BD, which has drawbacks due to its poor water solubility and low absorption. Additionally, since commercially available medications for EC treatment are created and approved for adult patients, administering them to children sometimes requires an off-label use and an impromptu handling, which can result in therapeutic ineffectiveness. The DPE 3D approach was investigated to create Mini-Tablets (MTs) to suit the swallowing, palatability, and dose flexibility control requirements needed by paediatric patients. Additionally, DPE 3D and the inclusion of hydroxypropyl-beta-cyclodextrin in the initial powder mixture allowed for an improvement in the solubility and rate of BD dissolution in aqueous medium. Then, to accomplish a site-specific drug release at the intestinal level, MTs were coated with a layer of Eudragit FS 30D, an enteric polymer responsive at pH > 7.0 values. In vitro release experiments showed that film-coated MTs were suitable in terms of size and dose, enabling potential therapeutic customization and targeted delivery of BD to the colon.

Automated summary

The study aimed to create a solid oral formulation of budesonide (BD) loaded with direct powder extrusion (DPE) 3D printing and fluid bed coating techniques for the treatment of eosinophilic colitis (EC) in paediatric patients. BD, the preferred medication for EC treatment, has poor water solubility and low absorption. The DPE 3D approach was used to create Mini-Tablets (MTs) suitable for paediatric patients, and the inclusion of hydroxypropyl-beta-cyclodextrin improved the solubility and dissolution rate of BD. The MTs were coated with an enteric polymer to achieve site-specific drug release at the intestinal level.